Skip to main content
Top
Published in: BMC Medicine 1/2023

Open Access 01-12-2023 | Hyperparathyroidism | Research article

Investigating the risk of metabolic and cardiovascular comorbidities among patients with parathyroid cancer: a nationwide representative cohort study in Taiwan

Authors: Ming-Chieh Tsai, Min-Shu Hsu, Hsin-Yin Hsu, Tzu-Lin Yeh, Chun-Ju Chiang, Wen-Chung Lee, Jing-Rong Jhuang, Shih-Ping Cheng, Po-Jung Tseng, Kuo-Liong Chien

Published in: BMC Medicine | Issue 1/2023

Login to get access

Abstract

Background

This study aimed to determine whether primary parathyroid cancer patients were associated with increased metabolic and cardiovascular comorbidities in comparison to the general population.

Methods

We used the National Taiwan Cancer Registry Database to construct a cohort of patients with parathyroid cancer from January 1, 2004, to December 31, 2019. We compared the incidence of hypertension, diabetes mellitus, hyperlipidemia, atrial fibrillation, coronary heart disease, and heart failure with the general population matched based on a propensity score in a one-to-five fashion.

Results

A total of 72 parathyroid cancer patients and 360 matched general population (mean age: 55 years; 59% women) were included, with different exclusive numbers for each metabolic and cardiovascular comorbidity cohort. The number of cases based on a total of 2347.7 person-years of observation included 53 deaths, 29 hypertension, 9 diabetes, 13 hyperlipidemia, 10 atrial fibrillation, 18 coronary artery disease, and 13 heart failure. According to multivariate analysis, parathyroid cancer remained significantly associated with diabetes [hazard ratio (HR): 9.28; 95% confidence interval (CI): 1.72–50.07], hyperlipidemia (HR: 5.86; 95% CI: 1.61–21.31), and heart failure (HR: 4.46; 95% CI: 1.18–16.84). Sub-distribution of competing mortality events and subgroup analysis showed robust evidence of metabolic and cardiovascular comorbidities. This national cohort study demonstrated that adult parathyroid cancer patients had a significantly higher incidence of diabetes mellitus, hyperlipidemia, and heart failure than the general population.

Conclusions

An increased risk of metabolic and cardiac comorbidities among parathyroid cancer patients required great caution.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lee PK, Jarosek SL, Virnig BA, Evasovich M, Tuttle TM. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109(9):1736–41.CrossRefPubMed Lee PK, Jarosek SL, Virnig BA, Evasovich M, Tuttle TM. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109(9):1736–41.CrossRefPubMed
2.
go back to reference Sadler C, Gow KW, Beierle EA, Doski JJ, Langer M, Nuchtern JG, et al. Parathyroid carcinoma in more than 1,000 patients: a population-level analysis. Surgery. 2014;156(6):1622–9; discussion 9–30. Sadler C, Gow KW, Beierle EA, Doski JJ, Langer M, Nuchtern JG, et al. Parathyroid carcinoma in more than 1,000 patients: a population-level analysis. Surgery. 2014;156(6):1622–9; discussion 9–30.
3.
go back to reference Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985–1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999;86(3):538–44. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985–1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999;86(3):538–44.
4.
go back to reference Asare EA, Sturgeon C, Winchester DJ, Liu L, Palis B, Perrier ND, et al. Parathyroid carcinoma: an update on treatment outcomes and prognostic factors from the National Cancer Data Base (NCDB). Ann Surg Oncol. 2015;22(12):3990–5.CrossRefPubMed Asare EA, Sturgeon C, Winchester DJ, Liu L, Palis B, Perrier ND, et al. Parathyroid carcinoma: an update on treatment outcomes and prognostic factors from the National Cancer Data Base (NCDB). Ann Surg Oncol. 2015;22(12):3990–5.CrossRefPubMed
5.
go back to reference Villar-del-Moral J, Jiménez-García A, Salvador-Egea P, Martos-Martínez JM, Nuño-Vázquez-Garza JM, Serradilla-Martín M, et al. Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study. Surgery. 2014;156(5):1132–44.CrossRefPubMed Villar-del-Moral J, Jiménez-García A, Salvador-Egea P, Martos-Martínez JM, Nuño-Vázquez-Garza JM, Serradilla-Martín M, et al. Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study. Surgery. 2014;156(5):1132–44.CrossRefPubMed
6.
go back to reference Limberg J, Stefanova D, Ullmann TM, Thiesmeyer JW, Bains S, Beninato T, et al. The use and benefit of adjuvant radiotherapy in parathyroid carcinoma: a national cancer database analysis. Ann Surg Oncol. 2021;28(1):502–11.CrossRefPubMed Limberg J, Stefanova D, Ullmann TM, Thiesmeyer JW, Bains S, Beninato T, et al. The use and benefit of adjuvant radiotherapy in parathyroid carcinoma: a national cancer database analysis. Ann Surg Oncol. 2021;28(1):502–11.CrossRefPubMed
7.
8.
go back to reference Owen RP, Silver CE, Pellitteri PK, Shaha AR, Devaney KO, Werner JA, et al. Parathyroid carcinoma: a review. Head Neck. 2011;33(3):429–36.PubMed Owen RP, Silver CE, Pellitteri PK, Shaha AR, Devaney KO, Werner JA, et al. Parathyroid carcinoma: a review. Head Neck. 2011;33(3):429–36.PubMed
9.
go back to reference Xue S, Chen H, Lv C, Shen X, Ding J, Liu J, et al. Preoperative diagnosis and prognosis in 40 parathyroid carcinoma patients. Clin Endocrinol (Oxf). 2016;85(1):29–36.CrossRefPubMed Xue S, Chen H, Lv C, Shen X, Ding J, Liu J, et al. Preoperative diagnosis and prognosis in 40 parathyroid carcinoma patients. Clin Endocrinol (Oxf). 2016;85(1):29–36.CrossRefPubMed
10.
go back to reference Ryhänen EM, Leijon H, Metso S, Eloranta E, Korsoff P, Ahtiainen P, et al. A nationwide study on parathyroid carcinoma. Acta Oncol. 2017;56(7):991–1003.CrossRefPubMed Ryhänen EM, Leijon H, Metso S, Eloranta E, Korsoff P, Ahtiainen P, et al. A nationwide study on parathyroid carcinoma. Acta Oncol. 2017;56(7):991–1003.CrossRefPubMed
11.
go back to reference Christakis I, Silva AM, Kwatampora LJ, Warneke CL, Clarke CN, Williams MD, et al. Oncologic progress for the treatment of parathyroid carcinoma is needed. J Surg Oncol. 2016;114(6):708–13.CrossRefPubMed Christakis I, Silva AM, Kwatampora LJ, Warneke CL, Clarke CN, Williams MD, et al. Oncologic progress for the treatment of parathyroid carcinoma is needed. J Surg Oncol. 2016;114(6):708–13.CrossRefPubMed
12.
go back to reference Luboshitzky R, Chertok-Schaham Y, Lavi I, Ishay A. Cardiovascular risk factors in primary hyperparathyroidism. J Endocrinol Invest. 2009;32(4):317–21.CrossRefPubMed Luboshitzky R, Chertok-Schaham Y, Lavi I, Ishay A. Cardiovascular risk factors in primary hyperparathyroidism. J Endocrinol Invest. 2009;32(4):317–21.CrossRefPubMed
13.
go back to reference Concistrè A, Grillo A, La Torre G, Carretta R, Fabris B, Petramala L, et al. Ambulatory blood pressure monitoring-derived short-term blood pressure variability in primary hyperparathyroidism. Endocrine. 2018;60(1):129–37.CrossRefPubMed Concistrè A, Grillo A, La Torre G, Carretta R, Fabris B, Petramala L, et al. Ambulatory blood pressure monitoring-derived short-term blood pressure variability in primary hyperparathyroidism. Endocrine. 2018;60(1):129–37.CrossRefPubMed
14.
go back to reference Bolland MJ, Grey AB, Gamble GD, Reid IR. Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab. 2005;90(3):1525–30.CrossRefPubMed Bolland MJ, Grey AB, Gamble GD, Reid IR. Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab. 2005;90(3):1525–30.CrossRefPubMed
15.
go back to reference Herrmann G, Hehrmann R, Scholz HC, Atkinson M, Lichtlen P, von zur Mühlen A, et al. Parathyroid hormone in coronary artery disease--results of a prospective study. J Endocrinol Invest. 1986;9(4):265–71. Herrmann G, Hehrmann R, Scholz HC, Atkinson M, Lichtlen P, von zur Mühlen A, et al. Parathyroid hormone in coronary artery disease--results of a prospective study. J Endocrinol Invest. 1986;9(4):265–71.
16.
go back to reference Han D, Trooskin S, Wang X. Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism. J Endocrinol Invest. 2012;35(6):548–52.PubMed Han D, Trooskin S, Wang X. Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism. J Endocrinol Invest. 2012;35(6):548–52.PubMed
17.
go back to reference Tassone F, Gianotti L, Baffoni C, Cesario F, Magro G, Pellegrino M, et al. Prevalence and characteristics of metabolic syndrome in primary hyperparathyroidism. J Endocrinol Invest. 2012;35(9):841–6.PubMed Tassone F, Gianotti L, Baffoni C, Cesario F, Magro G, Pellegrino M, et al. Prevalence and characteristics of metabolic syndrome in primary hyperparathyroidism. J Endocrinol Invest. 2012;35(9):841–6.PubMed
18.
go back to reference Joborn H, Lundin L, Hvarfner A, Johansson G, Wide L, Ljunghall S. Serum electrolytes and parathyroid hormone in patients in a coronary care unit. J Intern Med. 1989;225(1):9–14.CrossRefPubMed Joborn H, Lundin L, Hvarfner A, Johansson G, Wide L, Ljunghall S. Serum electrolytes and parathyroid hormone in patients in a coronary care unit. J Intern Med. 1989;225(1):9–14.CrossRefPubMed
19.
go back to reference Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation. 1997;96(6):1755–60.CrossRefPubMed Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation. 1997;96(6):1755–60.CrossRefPubMed
20.
go back to reference Procopio M, Barale M, Bertaina S, Sigrist S, Mazzetti R, Loiacono M, et al. Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine. 2014;47(2):581–9.CrossRefPubMed Procopio M, Barale M, Bertaina S, Sigrist S, Mazzetti R, Loiacono M, et al. Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine. 2014;47(2):581–9.CrossRefPubMed
21.
go back to reference Yu N, Donnan PT, Flynn RW, Murphy MJ, Smith D, Rudman A, et al. Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf). 2010;73(1):30–4. Yu N, Donnan PT, Flynn RW, Murphy MJ, Smith D, Rudman A, et al. Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf). 2010;73(1):30–4.
22.
go back to reference Yeh TL, Hsieh CT, Hsu HY, Tsai MC, Wang CC, Lin CY, et al. The risk of ischemic stroke in head and neck cancer patients and those who were treated with radiotherapy: a population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2022;31(5):1111–8.CrossRefPubMed Yeh TL, Hsieh CT, Hsu HY, Tsai MC, Wang CC, Lin CY, et al. The risk of ischemic stroke in head and neck cancer patients and those who were treated with radiotherapy: a population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2022;31(5):1111–8.CrossRefPubMed
23.
go back to reference Kalla A, Krishnamoorthy P, Gopalakrishnan A, Garg J, Patel NC, Figueredo VM. Primary hyperparathyroidism predicts hypertension: results from the National Inpatient Sample. Int J Cardiol. 2017;227:335–7.CrossRefPubMed Kalla A, Krishnamoorthy P, Gopalakrishnan A, Garg J, Patel NC, Figueredo VM. Primary hyperparathyroidism predicts hypertension: results from the National Inpatient Sample. Int J Cardiol. 2017;227:335–7.CrossRefPubMed
24.
go back to reference Mendoza-Zubieta V, Gonzalez-Villaseñor GA, Vargas-Ortega G, Gonzalez B, Ramirez-Renteria C, Mercado M, et al. High prevalence of metabolic syndrome in a mestizo group of adult patients with primary hyperparathyroidism (PHPT). BMC Endocr Disord. 2015;15:16.CrossRefPubMedPubMedCentral Mendoza-Zubieta V, Gonzalez-Villaseñor GA, Vargas-Ortega G, Gonzalez B, Ramirez-Renteria C, Mercado M, et al. High prevalence of metabolic syndrome in a mestizo group of adult patients with primary hyperparathyroidism (PHPT). BMC Endocr Disord. 2015;15:16.CrossRefPubMedPubMedCentral
25.
go back to reference Koubaity O, Mandry D, Nguyen-Thi PL, Bihain F, Nomine-Criqui C, Demarquet L, et al. Coronary artery disease is more severe in patients with primary hyperparathyroidism. Surgery. 2020;167(1):149–54.CrossRefPubMed Koubaity O, Mandry D, Nguyen-Thi PL, Bihain F, Nomine-Criqui C, Demarquet L, et al. Coronary artery disease is more severe in patients with primary hyperparathyroidism. Surgery. 2020;167(1):149–54.CrossRefPubMed
26.
go back to reference Wetzel J, Pilz S, Grübler MR, Fahrleitner-Pammer A, Dimai HP, von Lewinski D, et al. Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism: The EPATH trial. J Clin Hypertens (Greenwich). 2017;19(11):1173–80.CrossRefPubMed Wetzel J, Pilz S, Grübler MR, Fahrleitner-Pammer A, Dimai HP, von Lewinski D, et al. Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism: The EPATH trial. J Clin Hypertens (Greenwich). 2017;19(11):1173–80.CrossRefPubMed
27.
28.
go back to reference Hagström E, Lundgren E, Rastad J, Hellman P. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol. 2006;155(1):33–9.CrossRefPubMed Hagström E, Lundgren E, Rastad J, Hellman P. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol. 2006;155(1):33–9.CrossRefPubMed
29.
go back to reference Pang PK, Wang R, Shan J, Karpinski E, Benishin CG. Specific inhibition of long-lasting, L-type calcium channels by synthetic parathyroid hormone. Proc Natl Acad Sci U S A. 1990;87(2):623–7.CrossRefPubMedPubMedCentral Pang PK, Wang R, Shan J, Karpinski E, Benishin CG. Specific inhibition of long-lasting, L-type calcium channels by synthetic parathyroid hormone. Proc Natl Acad Sci U S A. 1990;87(2):623–7.CrossRefPubMedPubMedCentral
30.
go back to reference Rashid G, Bernheim J, Green J, Benchetrit S. Parathyroid hormone stimulates the endothelial expression of vascular endothelial growth factor. Eur J Clin Invest. 2008;38(11):798–803.CrossRefPubMed Rashid G, Bernheim J, Green J, Benchetrit S. Parathyroid hormone stimulates the endothelial expression of vascular endothelial growth factor. Eur J Clin Invest. 2008;38(11):798–803.CrossRefPubMed
31.
go back to reference Pepe J, Cipriani C, Sonato C, Raimo O, Biamonte F, Minisola S. Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur J Endocrinol. 2017;177(6):R297–r308.CrossRefPubMed Pepe J, Cipriani C, Sonato C, Raimo O, Biamonte F, Minisola S. Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur J Endocrinol. 2017;177(6):R297–r308.CrossRefPubMed
Metadata
Title
Investigating the risk of metabolic and cardiovascular comorbidities among patients with parathyroid cancer: a nationwide representative cohort study in Taiwan
Authors
Ming-Chieh Tsai
Min-Shu Hsu
Hsin-Yin Hsu
Tzu-Lin Yeh
Chun-Ju Chiang
Wen-Chung Lee
Jing-Rong Jhuang
Shih-Ping Cheng
Po-Jung Tseng
Kuo-Liong Chien
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2023
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-023-02946-z

Other articles of this Issue 1/2023

BMC Medicine 1/2023 Go to the issue